(Press-News.org) TUCSON, Ariz. and LEBANON, N.H., November 29, 2023 — Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) and Celdara Medical today announced the signing of a Memorandum of Understanding (MOU) aimed at identifying and advancing promising new therapeutics in areas of high unmet medical need. Under the terms of this agreement, both organizations look to expand opportunities to provide financial support for the development of early-stage therapeutics by exchanging non-competitive information submitted in academic funding proposals.
Launched in June 2022, TRxA is a global drug discovery and development accelerator focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge small molecule therapeutics from the lab to patients. TRxA leverages C-Path’s expertise in translational and regulatory science to provide vital funding and drug development expertise to support its grantees in developing comprehensive data packages for potential drug candidates, a key to garnering interest from biotechnology and pharmaceutical companies to invest in clinical trials.
Since its founding in 2008, Celdara Medical has built a robust pipeline of potential therapeutics for diseases with unmet needs, sourced from across the nation and globally. Many of these pipeline opportunities align with TRxA’s strategic objectives, as does the shared focus on and primacy of patient need and experience.
Dr. Jake Reder, Co-founder, and Chief Executive Officer of Celdara Medical, expressed his enthusiasm for the collaboration, stating, “At Celdara Medical, we advance therapies with the potential to make a meaningful difference in the lives of patients. This collaboration with TRxA will improve the efficiency of both organizations, expanding complementary access to our respective innovation pipelines.”
Dr. Julie Coleman, Director at Celdara Medical, added, “This MOU reflects our shared commitment to breaking down barriers in drug development. By sharing resources and expertise with TRxA, we are poised to make significant strides in identifying important inventions and advancing treatments for patients with urgent medical needs.”
Dr. Maaike Everts, Executive Director of C-Path’s TRxA, also shared her perspective on the collaboration, stating, “Drug discovery and development is a team sport; many types of expertise, funding models and organizations need to come together to mature an idea coming out of an academic institution into a therapy available to patients. I am very excited to work together with Celdara Medical to find the best environment and expertise needed to ensure our best and brightest ideas get nurtured into new medicines. The exchange of information under this MOU will be a great benefit to the scientists who approach us with their ideas for novel drugs.”
The MOU between C-Path and Celdara Medical highlights the significance of collaboration and information sharing in delivering innovative therapies to patients. Together, the two organizations are committed to improving healthcare worldwide.
About Critical Path Institute
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 54% funded by the FDA/HHS, totaling $19,436,549, and 46% funded by non-government source(s), totaling $16,373,368. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
About C-Path’s Translational Therapeutics Accelerator (TRxA)
Critical Path Institute’s Translational Therapeutics Accelerator (TRxA) is a not-for-profit global drug accelerator focused on supporting academic scientists in advancing novel therapeutics from university-based labs to drug development pipelines of pharmaceutical companies and, ultimately, the clinic. As a neutral convener of patient groups, academia, pharmaceutical companies and regulatory agencies, C-Path brings a breadth of scientific and drug development planning not available in other accelerator programs. TRxA is uniquely situated to leverage the expertise available through C-Path’s >20 disease-based consortia, as well as regulatory expertise and project management, to empower academic investigators to succeed in bringing safe and effective treatments to patients.
About Celdara Medical
Celdara Medical was founded by Drs. Jake Reder and Michael Fanger in 2008 and is headquartered at the Dartmouth Regional Technology Center (DRTC) in Lebanon, NH. Celdara Medical builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. Celdara Medical partners with inventors and their institutions, providing the developmental, financial, and business acumen required to bridge discovery and profitability. With robust funding options, a diverse and high impact Programmatic pipeline, and partnerships with world-class academic institutions and industry leaders, Celdara Medical navigates all aspects of a complex industry, accelerating science to improve human health. Further information about Celdara Medical is available at celdaramedical.com.
Media Contact:
Kissy Black
C-Path
615.310.1894
kblack@c-path.org
END
C-Path’s Translational Therapeutics Accelerator and Celdara Medical announce pipeline-focused MOU
2023-11-30
ELSE PRESS RELEASES FROM THIS DATE:
AI image generator Stable Diffusion perpetuates racial and gendered stereotypes, study finds
2023-11-29
What does a person look like? If you use the popular artificial intelligence image generator Stable Diffusion to conjure answers, too frequently you’ll see images of light-skinned men.
Stable Diffusion’s perpetuation of this harmful stereotype is among the findings of a new University of Washington study. Researchers also found that, when prompted to create images of “a person from Oceania,” for instance, Stable Diffusion failed to equitably represent Indigenous peoples. Finally, the generator tended to sexualize images of women from certain Latin American countries (Colombia, Venezuela, Peru) as well as those from Mexico, India and Egypt.
The researchers will present ...
ORNL joins consortium to tackle scientific AI’s next great milestone
2023-11-29
The Department of Energy’s Oak Ridge National Laboratory has joined a global consortium of scientists from federal laboratories, research institutes, academia and industry to address the challenges of building large-scale artificial intelligence systems and advancing trustworthy and reliable AI for scientific discovery.
The partnership, known as the Trillion Parameter Consortium, or TPC, seeks to grow and improve large-scale generative AI models aimed at tackling complex scientific challenges. These include the development of scalable model architectures and related training strategies, as well as data organization ...
UT Health San Antonio launches Center for Global and Community Oral Health
2023-11-29
The School of Dentistry of The University of Texas Health Science Center at San Antonio has launched the Center for Global and Community Oral Health, designed to bring together various existing outreach and research programs under one umbrella to study and develop solutions to the most pressing dental challenges facing the global population.
“Our vision is to transform community and global oral health through education, research and innovation,” said Brij B. Singh, PhD, associate dean of research for the dental ...
Breakthrough study shows exercise improves cognitive health for people with Down syndrome
2023-11-29
An exploratory study has shown that light, regular exercise can improve the cognitive, as well as physical, health of adults with Down syndrome.
The Mindsets study, published today [29 November] in the International Journal of Environmental Research and Public Health, is the first to investigate the effects of physical and cognitive exercise on people with Down syndrome, and it found that short bursts of walking can lead to improved information processing and attention after just eight weeks.
The role that exercise can play in cognitive growth represents a breakthrough in thinking about what’s ...
Long-standing hormone treatment for donated hearts found to be ineffective
2023-11-29
Doctors managing deceased organ donors routinely treat the donors’ bodies with thyroid hormones in a bid to preserve heart function and increase the quantity and quality of hearts and other organs available for transplantation. However, according to a recent clinical trial led by researchers at Washington University School of Medicine in St. Louis and Mid-America Transplant in St. Louis, routine thyroid hormone intervention is not effective at achieving these goals, and may even cause harm.
The study is published Nov. 30 in The New England Journal of Medicine.
“There have been ...
Catalysts of change: Young scientists spearhead breakthrough COVID-19 research in international collaboration
2023-11-29
A recent groundbreaking study, published in Nature Nanotechnology, sheds new light on the coronavirus's behavior, particularly its ability to remain attached under various mechanical stresses and the implications for person-to-person transmission. The paper, titled “Single-molecule force stability of the SARS-CoV-2–ACE2 interface in variants-of-concern,” is the result of a collaborative effort led by scientists from Auburn University, Ludwig Maximilian University of Munich, and Utrecht University. This research offers an unprecedented molecular-level understanding of the virus and raises ...
With some forms of TBI, non-deployed vets have higher risk of epilepsy than deployed
2023-11-29
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, NOVEMBER 29, 2023
MINNEAPOLIS – A study of post-9/11 veterans shows that those with moderate or severe traumatic brain injury (TBI) who have never been deployed have a higher risk of epilepsy than those who have been deployed. The study is published in the November 29, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
“We anticipated that deployment would be linked to a higher risk of epilepsy among post-9/11 veterans with TBI given the potential higher risk for a blast or combat ...
Certain migraine medications may be more effective than Ibuprofen
2023-11-29
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, NOVEMBER 29, 2023
MINNEAPOLIS – For many people with migraine, it can be difficult to find a treatment that is effective and reliable, and information on how medications compare to one another is lacking. A new study draws data from nearly 300,000 people using a smartphone app to help people make decisions about their medications. The study found that certain migraine medications like triptans, ergots and anti-emetics may be two to five times more effective than ibuprofen ...
Embedding fibers to undo the tapestry of memory loss in Alzheimer's disease
2023-11-29
Every 65 seconds, someone in the United States develops Alzheimer’s disease, a devastating form of dementia that affects 6.2 million Americans.
Though it was initially identified almost 120 years ago, Alzheimer’s disease is a progressive neurological disorder with no cure and few treatments. It starts out with minor memory loss that, over time, advances to a mental decline so severe, individuals have difficulty even swallowing.
Xiaoting Jia, associate professor in the Bradley Department of Electrical ...
Novel study finds aspirin-free regimen benefits patients with LVAD
2023-11-29
The ARIES-HM3 Randomized Clinical Trial assessed the safety and efficacy of excluding aspirin from the antithrombotic regimen in patients with advanced heart failure who have undergone implantation of a fully magnetically levitated left ventricular assist device (LVAD).
“We can now safely say that not giving aspirin is not only safe from a thromboembolic risk profile but results in improved adverse event rate by a significant reduction in non-surgical bleeding which is a well-known complication related to LVAD therapy,” said Mirnela Byku, M.D., Ph.D., MBA, co-author of the study and director of the UNC Durable Mechanical ...